Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Genentech, Inc.

Yingjie Lai

Jun Liang

Steven R Magnuson

Birong Zhang

Simon Charles Goodacre

Karen Williams

Li Chen

Michael Patrick Dillon

Lichun Feng

Minmin Yang

Vickie H Tsui

Calum Macleod

Toby Jonathan Blench

Yan Lou

Ronald Charles Hawley

Vickie Hsiao-Wei Tsui

Rama K Kondru

Nolan James Dewdney

Kirk D Robarge

Mark S Stanley

Calum MacLeod

Aihe Zhou

Charles Ellwood

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy. 

Pyrazolopyridine compounds, compositions and methods of use

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted thiadiazolyl, and R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

[object Object]

Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I. 

Azabenzothiazole compounds, compositions and methods of use

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof. 

Janus kinase inhibitor compounds and methods

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-II: wherein, variables Q, Q, R, X, Y, Y, Y, Y, Y, Y, m, and p are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-II and at least one carrier, diluent or excipient.

Inhibitors of Bruton's tyrosine kinase

Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Growing community of inventors

Cupertino, CA, United States of America

Yingjie Lai